The company Orchard Therapeutics (Netherlands) BV has stated its willingness to participate in a joint assessment of the autologous gene therapy Libmeldy (atidarsagene autotemcel) within the…
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Joint HTA assessment on autologous gene therapy Libmeldy ongoing
Pharmaceutical Developments on Haemophilia
This report, written by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Haemophilia and provides an overview of new pharmaceutical developments regarding…
Pharmaceutical Developments on Alzheimer’s Disease
This report, by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Alzheimer’s disease and provides an overview of new pharmaceutical developments regarding…